Exhibit 060 · Company press release
BioNTech announces new collaboration to develop HIV and tuberculosis programs
This partnership includes an initial equity investment of $55 million, which is expected to close within the next week.
The Gates Foundation made a $55 million equity investment in BioNTech, tied to HIV and tuberculosis programs, with total collaboration funding of up to about $100 million.
- Source
- BioNTech SE
- Date
- September 2019
- Quoted from
- BioNTech press release, 4 September 2019 (headline subtitle: collaboration "could reach up to $100 million in total funding")
- Grade
- Primary record
- Document
- https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2019/09/biontech-announces-new-collaboration-develop-hiv-and.html
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
- Note
- ImpactAlpha reports that the investment predated BioNTech's COVID-19 work and that the foundation gave no direct support to the Pfizer–BioNTech vaccine candidate: https://impactalpha.com/gates-foundations-role-in-pfizers-promising-covid-vaccine-is-part-of-a-strategy-not-a-conspiracy/